This article is more than 5 years old. Information may no longer be current.

First neurotrophic keratitis patient treated with Oxervate

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The first U.S. patient has been treated with Oxervate eye drops for neurotrophic keratitis, Dompé announced in a press release.

Oxervate (cenegermin-bkbj), a recombinant human nerve growth factor that was approved by the FDA in August 2018, has the potential to resolve neurotrophic keratitis in one 8-week treatment cycle.

“I am excited to be among the first physicians to treat neurotrophic keratitis patients with this new therapy,” Giacomina Massaro-Giordano, MD, of the Scheie Eye Institute at the University of Pennsylvania and an investigator in the Oxervate clinical trials, said in the release. “This newly approved therapy provides clinical improvements for NK patients, many of whom are at risk for losing their sight, and treatment options to help them were previously limited to symptom management.”

Oxervate is commercially available in the U.S. through Accredo specialty pharmacy. Dompé has also begun Dompé Connect to Care, a support program that provides educational resources on neurotrophic keratitis, and the Oxervate Co-pay Card Program and the Dompé Patient Assistance Program, which offer financial assistance to eligible patients, the release said.